p185BCR/ABL has a lower sensitivity than p210BCR/ABL to the allosteric inhibitor GNF-2 in Philadelphia chromosome-positive acute lymphatic leukemia

Haematologica

Volumn 97, Issue 2, 2012, Pages 251-257

  Mian, Afsar A ^a   Metodieva, Anna ^a   Najajreh, Yousef ^b   Ottmann, Oliver G ^a   Mahajna, Jamal ^c   Ruthardt, Martin ^a  

^a GOETHE UNIVERSITY   (Germany)

^b AL QUDS UNIVERSITY   (Palestine)

^c MIGAL GALILEE TECHNOLOGY CENTER   (Israel)

Author keywords

Acute lymphatic leukemia; Allosteric inhibition; Bcr abl; Molecular therapy; Philadelphia chromosome

Indexed keywords

ANTINEOPLASTIC AGENT; BCR ABL PROTEIN; GNF 2; PROTEIN P185; UNCLASSIFIED DRUG;

ACUTE LYMPHOCYTIC LEUKEMIA; ADULT; ALLOSTERISM; ANTINEOPLASTIC ACTIVITY; ARTICLE; CANCER CELL CULTURE; CANCER INHIBITION; CELL PROLIFERATION; CELL TRANSFORMATION; CONTROLLED STUDY; DRUG SENSITIVITY; GENE EXPRESSION; GENE MUTATION; GENETIC DIFFERENCE; GENETIC RESISTANCE; HUMAN; HUMAN CELL; PHILADELPHIA CHROMOSOME POSITIVE CELL;

ALLOSTERIC REGULATION; CELL LINE, TUMOR; FUSION PROTEINS, BCR-ABL; HUMANS; LEUKEMIA, MYELOGENOUS, CHRONIC, BCR-ABL POSITIVE; PYRIMIDINES;

EID: 84856488091     PISSN: 03906078     EISSN: 15928721     Source Type: Journal    
DOI: 10.3324/haematol.2011.047191     Document Type: Article

References (17)

1. Radich JP. The biology of CML blast crisis. Hematology Am Soc Hematol Educ Program. 2007:384-91.
2. Faderl S, Talpaz M, Estrov Z, O'Brien S, Kurzrock R, Kantarjian HM. The biology of chronic myeloid leukemia. N Engl J Med. 1999;341(3):164-72.
3. Melo JV, Barnes DJ. Chronic myeloid leukaemia as a model of disease evolution in human cancer. Nat Rev Cancer. 2007;7 (6):441-53.
4. Ottmann OG, Wassmann B. Treatment of Philadelphia chromosome-positive acute lymphoblastic leukemia. Hematology Am Soc Hematol Educ Program. 2005:118-22.
5. Harnois T, Constantin B, Rioux A, Grenioux E, Kitzis A, Bourmeyster N. Differential interaction and activation of Rho family GTPases by p210bcr-abl and p190bcr-abl. Oncogene. 2003;22(41):6445-54.
6. Gokbuget N, Hoelzer D. Treatment of adult acute lymphoblastic leukemia. Hematology Am Soc Hematol Educ Program. 2006:133-41.
7. Zheng X, Oancea C, Henschler R, Moore MA, Ruthardt M. Reciprocal t(9;22) ABL/BCR fusion proteins: leukemogenic potential and effects on B cell commitment. PLoS One. 2009;4(10):e7661.
8. Li S, Ilaria RL Jr, Million RP, Daley GQ, Van Etten RA. The P190, P210, and P230 forms of the BCR/ABL oncogene induce a similar chronic myeloid leukemia-like syndrome in mice but have different lymphoid leuke-mogenic activity. J Exp Med. 1999;189(9): 1399-412.
9. Ramirez P, DiPersio JF. Therapy options in imatinib failures. Oncologist. 2008;13(4): 424-34.
10. Hantschel O, Superti-Furga G. Regulation of the c-Abl and Bcr-Abl tyrosine kinases. Nat Rev Mol Cell Biol. 2004;5(1):33-44.
11. Adrian FJ, Ding Q, Sim T, Velentza A, Sloan C, Liu Y, et al. Allosteric inhibitors of Bcr-abl-dependent cell proliferation. Nat Chem Biol. 2006;2(2):95-102.
12. Beissert T, Hundertmark A, Kaburova V, Travaglini L, Mian AA, Nervi C, et al. Targeting of the N-terminal coiled coil oligomerization interface by a helix-2 pep-tide inhibits unmutated and imatinib-resistant BCR/ABL. Int J Cancer. 2008;122(12): 2744-52.
13. Nijmeijer BA, Szuhai K, Goselink HM, van Schie ML, van der Burg M, de Jong D, et al. Long-term culture of primary human lym-phoblastic leukemia cells in the absence of serum or hematopoietic growth factors. Exp Hematol. 2009;37(3):376-85.
14. Zhang J, Adrian FJ, Jahnke W, Cowan-Jacob SW, Li AG, Iacob RE, et al. Targeting Bcr-Abl by combining allosteric with ATP-binding-site inhibitors. Nature. 2010;463(7280): 501-6.
15. Mian AA, Oancea C, Zhao Z, Ottmann OG, Ruthardt M. Oligomerization inhibition, combined with allosteric inhibition, abrogates the transformation potential of T315I-positive BCR/ABL. Leukemia. 2009; 23(12):2242-7.
16. Lugo TG, Pendergast AM, Muller AJ, Witte ON. Tyrosine kinase activity and transformation potency of bcr-abl oncogene products. Science. 1990;247(4946):1079-82.
17. Ilaria RL Jr, Van Etten RA. P210 and P190(BCR/ABL) induce the tyrosine phos-phorylation and DNA binding activity of multiple specific STAT family members. J Biol Chem. 1996;271(49):31704-10.